HLA-DQB1*05:02 Allele Association with Anti-Tuberculosis Drug Induced Liver Injury: A Single-Hospital Based Study in Jakarta, Indonesia
DOI:
https://doi.org/10.31964/mltj.v9i2.547Keywords:
Anti-tuberculosis-drug induced liver injury, human leucocyte antigen-DQB1*05:02, polymerase chain reaction, tuberculosisAbstract
Past studies have delved into the genetic factors underlying anti-tuberculosis drug-induced liver injury (AT-DILI), primarily concentrating on polymorphisms in genes responsible for drug-metabolizing enzymes. However, the immune system's potential impact on drug adverse effects, specifically through genes such as HLA, has received limited attention. Previous research has notably revealed an association between HLA-DQB1*05 and AT-DILI, specifically the prevalence of the HLA-DQB*05:02 allele in AT-DILI patients. In light of this, our study aimed to investigate a potential link between HLA-DQB1*05:02 alleles and AT-DILI. In this study, we included 51 AT-DILI cases and 59 controls belonging to the Javanese ethnic group. The HLA-DQB1*05:02 genotypes were determined using a customized PCR-based typing method, and the results were further confirmed by analyzing five samples via the Luminex assay. Our findings revealed a significant association between HLA-DQA1*05: 02 and the risk of AT-DILI (P = 0.022; OR (95% CI) = 6.11 (1.25-29.74)). Moreover, the consistent results obtained from the Luminex assay validated the reliability of the custom PCR-based genotyping approach. This preliminary study sheds light on the relationship between the HLA-DQB1*05:02 allele and AT-DILI within the Indonesian population. Furthermore, our study demonstrates the dependability of custom PCR-based genotyping in detecting HLA-DQB1*05:02 alleles. Nevertheless, further research is imperative to corroborate and expand upon our findings.References
American Thoracic Society/Centers for Disease Control/Infectious Diseases Society of America. (2003). Treatment of tuberculosis. https://doi.org/10.1164/ajrccm.161.supplement_3.ats600
Bao, Y., Ma, X., Rasmussen, T. P., & Zhong, X. B. (2018). Genetic Variations Associated with Anti-Tuberculosis Drug-Induced Liver Injury. Current Pharmacology Reports. 4(3):171–181. https://doi.org/10.1007/s40495-018-0131-8
Barbarino, J. M., Kroetz, D. L., Klein, T. E., & Altman, R. B. (2015). PharmGKB summary: Very important pharmacogene information for human leukocyte antigen B. Pharmacogenetics and Genomics. 24(4):205-221
Chen, R., Zhang, Y., Tang, S., Lv, X., Wu, S., Sun, F., Xia, Y., & Zhan, S. Y. (2015a). The association between HLA-DQB1 polymorphism and antituberculosis drug-induced liver injury: A Case-Control Study. Journal of Clinical Pharmacy and Therapeutics. 40(1):110–115. https://doi.org/10.1111/jcpt.12211
Chen, R., Zhang, Y., Tang, S., Lv, X., Wu, S., Sun, F., Xia, Y., & Zhan, S. Y. (2015b). The association between HLA-DQB1 polymorphism and antituberculosis drug-induced liver injury: a Case-Control Study. Journal of Clinical Pharmacy and Therapeutics. 40(1):110–115. https://doi.org/10.1111/jcpt.12211
Daly, A. K., Donaldson, P. T., Bhatnagar, P., Shen, Y., Pe’er, I., Floratos, A., Daly, M. J., Goldstein, D. B., John, S., Nelson, M. R., Graham, J., Park, B. K., Dillon, J. F., Bernal, W., Cordell, H. J., Pirmohamed, M., Aithal, G. P., & Day, C. P. (2009). HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nature Genetics. 41(7):816–819. https://doi.org/10.1038/ng.379
Dunn, P. P. J. (2011). Human leucocyte antigen typing: techniques and technology, a critical appraisal. International Journal of Immunogenetics. 38(6):463–473. https://doi.org/10.1111/j.1744-313X.2011.01040.x
Garibyan, L., & Avashia, N. (2013). Polymerase chain reaction. Journal of Investigative Dermatology. 133(3):1–4. https://doi.org/10.1038/jid.2013.1
Hirata, K., Takagi, H., Yamamoto, M., Matsumoto, T., Nishiya, T., Mori, K., Shimizu, S., Masumoto, H., & Okutani, Y. (2008). Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: A preliminary case-control study. Pharmacogenomics Journal. 8(1):29–33. https://doi.org/10.1038/sj.tpj.6500442
Hosomichi, K., Shiina, T., Tajima, A., & Inoue, I. (2015). The impact of next-generation sequencing technologies on HLA research. Journal of Human Genetics. 60(11):665–673. https://doi.org/10.1038/jhg.2015.102
Johdi, N. A., Othman Sri Noraima, Abd Razak, Z., Mazlan, L., Sagap, I., & Jamal, R. (2016). The HLA DPB1*02:01:02 and DQB1*05:02:01 alleles as possible risk factors for colorectal carcinoma in the Malaysian population. Asia-Pacific Journal of Mol. Medicine. 6(2): 1-8
Khalil, M. I. (2021). Different Types of PCR. Global Scientific Journals. 9(2):758–768. https://doi.org/10.11216/gsj.2021.02.48315
Kibbe, W. A. (2007). OligoCalc: An online oligonucleotide properties calculator. Nucleic Acids Research, 35(SUPPL.2). https://doi.org/10.1093/nar/gkm234
Kuranov, A. B., Kozhamkulov, U. A., Vavilov, M. N., Belova, E. S., Bismilda, V. L., Alenova, A. H., Ismailov, S. S., & Momynaliev, K. T. (2014). HLA-class II alleles in patients with drug-resistant pulmonary tuberculosis in Kazakhstan. Tissue Antigens. 83(2): 106–112. https://doi.org/10.1111/tan.12279
Leiro-Fernández, V., Valverde, D., Vázquez-Gallardo, R., Constenla-Caramés, L., del Campo-Pérez, V., & Fernández-Villar, A. (2016). HLA-DQ B1*0201 and A1*0102 alleles are not responsible for antituberculosis drug-induced hepatotoxicity risk in Spanish population. Frontiers in Medicine. 3:34. https://doi.org/10.3389/fmed.2016.00034
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547852/. Accesed on 14 March 2021.
Lucena, M. I., Molokhia, M., Shen, Y., Urban, T. J., Aithal, G. P., Andrade, R. J., Day, C. P., Ruizcabello, F., Donaldson, P. T., Stephens, C., Pirmohamed, M., Romerogomez, M., Navarro, J. M., Fontana, R. J., Miller, M., Groome, M., Bondonguitton, E., Conforti, A., Stricker, B. H. C., … Daly, A. K. (2011). Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class i and II alleles. Gastroenterology. 141(1):338–347. https://doi.org/10.1053/j.gastro.2011.04.001
Maróstica, A. S., Nunes, K., Castelli, E. C., Silva, N. S. B., Weir, B. S., Goudet, J., & Meyer, D. (2022). How HLA diversity is apportioned: Influence of selection and relevance to transplantation. Philosophical Transactions of the Royal Society B: Biological Sciences, 377(1852): 20200420. https://doi.org/10.1098/rstb.2020.0420
Naderi, M., Hosseini, S. M., Behnampour, N., Shahramian, I., & Moradi, A. (2023). Association of HLADQ-B1 polymorphisms in three generations of chronic hepatitis B patients. Virus Research, 325:199036. https://doi.org/10.1016/j.virusres.2022.199036
Nicoletti, P., Werk, A. N., Sawle, A., Shen, Y., Urban, T. J., Coulthard, S. A., Bjornsson, E. S., Cascorbi, I., Floratos, A., Stammschulte, T., Gundert-Remy, U., Nelson, M. R., Aithal, G. P., & Daly, A. K. (2016). HLA-DRB1∗16:01-DQB1∗05:02 is a novel genetic risk factor for flupirtine-induced liver injury. Pharmacogenetics and Genomics. 26(5):218–224. https://doi.org/10.1097/FPC.0000000000000209
Perwitasari, D. A., Darmawan, E., Mulyani, U. A., Vlies, P. Van Der, Alffenaar, J. C., Atthobar, J., & Wilffert, B. (2018). Polymorphism of NAT2, CYP2E1, GST, and HLA Related to Drug-Induced Liver Injury in Indonesia Tuberculosis Patients. International Journal of Mycobacteriology. 7(4):380–386. https://doi.org/10.4103/ijmy.ijmy
Phillips, E., Bartlett, J. A., Sanne, I., Lederman, M. M., Hinkle, J., Rousseau, F., Dunn, D., Pavlos, R., James, I., Mallal, S. A., & Haas, D. W. (2013). Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. Journal of Acquired Immune Deficiency Syndromes. 62(2): e55-7. https://doi.org/10.1097/QAI.0b013e31827ca50f
Sahiratmadja, E., Penggoam, S., Maskoen, A. M., Pramono, A. P., Aryani, D., Rahayu, N. S., & Panigoro, R. (2018). Distribution of rs1801279 and rs1799930 Polymorphisms in NAT2 Gene among Population in Kupang, Nusa Tenggara Timur, Indonesia. The Indonesian Biomedical Journal. 10(1):56–61. https://doi.org/10.18585/inabj.v10i1.330
Salvado, M., ’Caro, J. L., ’Garcia, C., ’Rudilla, F., ’Zalba-Jadraque, L., ’Lopez, E., ’Sanjuan, E., ’Gamez, J., & ’Vidal-Taboada, J. M. (2022). HLA-DQB1*05:02, *05:03, and *03:01 alleles as risk factors for myasthenia gravis in a Spanish cohort. Neurological Sciences. 43(8):5057–5065.
Shang, P., Xia, Y., Liu, F., Wang, X., Yuan, Y., Hu, D., Tu, D., Chen, Y., Deng, P., Cheng, S., Zhou, L., Ma, Y., Zhu, L., Gao, W., Wang, H., Chen, D., Yang, L., He, P., Wu, S., … Zhan, S. (2011). Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS ONE. 6(7):e21836. https://doi.org/10.1371/journal.pone.0021836
Sharma, S. K., Balamurugan, A., Saha, P. K., Pandey, R. M., & Mehra, N. K. (2002). Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. American Journal of Respiratory and Critical Care Medicine. 166(7): 916–919. https://doi.org/10.1164/rccm.2108091
Singla, N., Gupta, D., Birbian, N., & Singh, J. (2014). Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity. Tuberculosis. 94(3):293–298. https://doi.org/10.1016/j.tube.2014.02.003
Soedarsono, S., & Riadi, A. R. W. (2020). Tuberculosis Drug-Induced Liver Injury. Jurnal Respirasi. 6(2):49. https://doi.org/10.20473/jr.v6-i.2.2020.49-54
Sun, F., Chen, Y., Xiang, Y., & Zhan, S. (2008). Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. The International Journal of Tuberculosis and Lung Disease : The Official Journal of the International Union against Tuberculosis and Lung Disease. 12(9):994–1002. http://www.ncbi.nlm.nih.gov/pubmed/18713495
Suvichapanich, S., Fukunaga, K., Zahroh, H., Mushiroda, T., Mahasirimongkol, S., & Toyo-oka, L. (2018). NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury : a genotype-based meta-analysis. Pharmacogenetics and Genomics. 28(7):167–176. https://doi.org/10.1097/FPC.0000000000000339
Tait, B. D. (2016). Detection of HLA antibodies in organ transplant recipients - triumphs and challenges of the solid phase bead assay. Frontiers in Immunology. 9(7):570. https://doi.org/10.3389/fimmu.2016.00570
Testi, M., Terracciano, C., Guagnano, A., Testa, G., Marfia, G. A., Pompeo, E., Andreani, M., & Massa, R. (2012). Association of HLA-DQB1*05:02 and DRB1*16 alleles with late-onset, nonthymomatous, AChR-Ab-positive myasthenia gravis. Autoimmune Diseases. ID541760. https://doi.org/10.1155/2012/541760
Tostmann, A., Boeree, M. J., Aarnoutse, R. E., De Lange, W. C. M., Van Der Ven, A. J. a M., & Dekhuijzen, R. (2008). Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. Journal of Gastroenterology and Hepatology. 23(2): 192–202. https://doi.org/10.1111/j.1440-1746.2007.05207.x
Untergasser, A., Cutcutache, I., Koressaar, T., Ye, J., Faircloth, B. C., Remm, M., & Rozen, S. G. (2012). Primer3-new capabilities and interfaces. Nucleic Acids Research, 40(15):e115. https://doi.org/10.1093/nar/gks596
Urban, T. J., Daly, A. K., & Aithal, G. P. (2014). Genetic Basis of Drug-Induced Liver Injury : Present and Future. 1Seminars in Liver Disease. 34(2): 123-133
Wang, P.-Y., Xie, S.-Y., Hao, Q., Zhang, C., & Jiang, B.-F. (2012). NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. The International Journal of Tuberculosis and Lung Disease : The Official Journal of the International Union against Tuberculosis and Lung Disease. 16(5):589–595. https://doi.org/10.5588/ijtld.11.0377
Wattanapokayakit, S., Mushiroda, T., Yanai, H., Wichukchinda, N., & Chuchottawon, C. (2016). NAT2 slow acetylator associated with anti-tuberculosis drug- induced liver injury in Thai patients. International Journal of Tuberculosis and Lung Disease. 20(10):1364–1369.
World Health Organization & World Health Organization. (2010). Treatment of tuberculosis: guidelines, 4th edition. World Health Organization. https://apps.who.int/iris/handle/10665/44165. Accessed on 6 June 2018.
World Health Organization (WHO). (2021). Global Tuberculosis Report 2021. https://www.who.int/publications/i/item/9789240037021. Accessed on 15 April 2021.
Yuliwulandari, R., Prayuni, K., Susilowati, R. W., Subagyo, S., Soedarsono, S., M Sofro, A. S., Tokunaga, K., & Shin, J.-G. (2019). NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in Indonesian population. Pharmacogenomics, 20(18):1303-1311. https://doi.org/10.2217/pgs-2019-0131.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Kinasih Prayuni, Hilyatuz Zahroh, Syafrizal Syafrizal, Rika Yuliwulandari
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Publishing your paper with Medical Laboratory Technology Journal (MLTJ) means that the author or authors retain the copyright in the paper. MLTJ granted an author(s) rights to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by MLTJ in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.
MLTJ journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially. MLTJ journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:
BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.SA: If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
